Background
==========

In the complex interaction of relationships that exist between the immune system and cancer, therapeutic vaccination can be considered as a valid approach to overcoming the established state of immunotolerance between the two systems \[[@B1],[@B2]\].

The use of dendritic cells (DC) derived from peripheral blood precursors and pulsed with tumor antigens forms the basis of experimental and clinical trials on antitumor vaccinations \[[@B3],[@B4]\]. Although numerous clinical studies have reported interesting objective regressions, case series are often small with limited overall response rates \[[@B5]\]. A recent review on antitumor vaccines, especially with regard to melanoma, attributed an overall response (OR) of 3.8%, with an *encouraging*7.1% for DC vaccines \[[@B6]\].

Although OR rates for vaccination are somewhat limited, results obtained with DC vaccinations can be considered promising, also because of the low toxicity observed \[[@B7]\]. The majority of these studies have aimed at demonstrating immunization against a single or a cocktail of well defined antigens and, considering the potentially enormous number of antigens presented by the tumor and remodelled over time \[[@B8],[@B9]\], it is rather surprising that any clinical responses have been observed at all \[[@B10]-[@B13]\]. However, in addition to the fundamental choice of antigens, the generation, cell culture, maturation status, and administration modalities of DC represent other critical steps needed for the good outcome of therapeutic vaccination.

At present, most authors use leukapheresis as source of DC \[[@B14]-[@B16]\]. Furthermore, the initial use of immature DC (iDC) has been replaced by that of DC matured *in vitro*(mDC) \[[@B17],[@B18]\]. Conversely, the number of DC to administer, vaccination scheduling and duration, and routes of administration have still to be defined \[[@B19]-[@B21]\].

Another critical and much discussed issue is the clinical use of cytokines as vaccination adjuvants. In particular, it is not clear whether the administration of interkeukin-2 (IL-2) is necessary, useful, or counterproductive for clinical results \[[@B22]-[@B26]\].

It is also difficult to carry out a critical review of DC studies because the evaluation criteria used (WHO, RECIST) do not adapt well to some clinical situations obtained with vaccination \[[@B27],[@B28]\]. The problem could, in part, be resolved by carrying out immunomonitoring, which is feasible for vaccinations with one or a small number of defined antigens, but much more complex when undefined antigen complexes are used \[[@B29]\].

We present an in-depth description of a phase I-II study of therapeutic vaccination using DC pulsed with autologous tumor lysate (ATL) or homogenate (ATH) and with keyhole limpet hemocyanin (KLH) in advanced melanoma patients. The study was begun in 2001 and was thus influenced by our own experience and by that of other authors.

Methods
=======

Patients
--------

From August 2001 to September 2005, 21 patients with advanced melanoma were entered onto the vaccination protocol using autologous DC pulsed with ATL or ATH and KLH. Eight patients were treated with immature DC (iDC) and 13 with mature DC (mDC). Inclusion criteria were age \< 70 years, histologically confirmed diagnosis of melanoma, measurable disease (excluding brain metastases), previous removal of one or more metastatic lesions from which a sufficient quantity of ATL/ATH was obtained for at least 6 vaccinations, Performance Status (PS) ≤ 2 (according to ECOG criteria), life expectancy more than 4 months.

Treatment
---------

The first 8 patients were treated with iDC (range 4.5 -- 82 × 10^6^) via subcutaneous or intradermal injection with an insulin needle. Several inoculations were made (average 6--8) near the groin or the armpit in non metastatic, non lymphadenectomized sites. A further 13 patients were treated with intradermal mDC (range 1.2--26 × 10^6^) alone following the abovementioned criteria, but with 8-10 inoculations. Subcutaneous IL-2 (Chiron, Milan, Italy) 3,000,000 IU/day was administered about 48 hours after each vaccination for 5 consecutive days. The first 4 vaccinations were carried out at intervals of 15 days and once a month thereafter.

Clinical evaluation (in partial acordance with RECIST criteria \[[@B28]\]), and delayed-type hypersensitivity (DTH) assessment were carried out before the first vaccination, after the 4th vaccination, and every 2 vaccinations thereafter. The disappearance of, or an important reduction in pre-existing lesions in concomitance with disease progression in other sites, was considered as a mixed response (MR). If progression did not compromise the patient\'s general conditions, several more vaccinations were carried out until progression was irrefutably documented. The best response obtained was considered for evaluation purposes. Toxicity or adverse events were assessed after each vaccine administration.

The study protocol was reviewed and approved by the local Ethics Committee, in accordance with ethical standards laid down in the 1964 Declaration of Helsinki, and authorized in July 2001 by the Italian Ministry of Health. All patients gave their informed written consent to receive treatment.

Autologous Tumor Lysate (ATL) preparation
-----------------------------------------

Surgically removed tumor samples were mechanically dispersed to create a single-cell suspension. The largest pieces were incubated at 37°C in enzyme mix (collagenase 0.1%, hyaluronidase 0.01%, DNAse 0.1%, Sigma, Milan, Italy) in RPMI 1640, (PAA Laboratories GmbH, Pasching, Austria) for 3 hours. At the end of incubation the pellets were washed 3 times with PBS and incubated for at least 20 minutes in sterile distilled water. Lysis was monitored by light microscope. Larger particles were removed by centrifugation (10 min at 600 *g*) and the supernatant was passed through a 0.2-μm filter. Protein contents were determined and aliquots were stored at -80°C until use, after verification of sterility.

Autologous Tumor Homogenate (ATH) preparation
---------------------------------------------

In some cases, the surgically removed tissue was stored at -80°C because the decision to vaccinate had still not been taken. Frozen tissue fragments were pulverized in a dismembrator after immersion in liquid nitrogen. Pulverized tissue was then suspended in PBS. After centrifugation, the supernatant was treated as described above.

DC generation
-------------

DC were prepared from peripheral blood monocytes (PBMC) obtained by leukapheresis without previous mobilization. Five to nine liters of blood were processed in each collection. PBMC were purified on Ficoll-Paque. An aliquot of PBMC was utilized immediately for DC generation and the rest was frozen in bags for use at a later date (4--5 bags/each collection).

PBMC were incubated in tissue culture flasks with CellGro DC medium (Cell Genix, Freiburg, Germany) at 10 × 10^6^cells/ml for 2 h. The non-adherent cells were discarded and the adherent cells were incubated in CellGro DC medium containing 1000 IU/ml rhIL-4 (Cell Genix, Freiburg, Germany) and 1000 IU/ml rhGM-CSF (Schering-Plough, Milan, Italy) for 7 days to generate a DC-enriched cell population. On day 6, 90% of the DC culture was pulsed with ATL/ATH (100 mg/ml), while the remaining 10% was pulsed with KLH (50 mg/ml). Both cultures were then incubated overnight. On day 7, the cells were defined as immature DC (iDC). After eliminating the previous culture medium, pulsed iDC were cultured for a further 2 days with a cocktail of cytokines (TNFα, IL-1β, IL-6, Endogen, Pierce Biotechnology, Rockford, USA; PGE~2~, Cayman Chemical, Ann Arbor, MI, USA). On day 9 they were defined as mature DC (mDC). iDC or mDc were removed, washed and suspended in sterile saline for therapeutic infusion into the patient (iDC, range 4.5 -- 82 × 10^6^; mDc, range 1.2--26 × 10^6^).

Phenotype analysis
------------------

iDC and mDC phenotypes were determined by single or two-color fluorescence analysis in cells labelled with monoclonal antibodies (mAbs) and fixed in paraformaldehyde 2%. The fluorescence was analyzed by a FACS Vantage flow cytometer (Becton Dickinson, Milan, Italy). mAbs specific for human CD1a, CD14, CD80, CD86, HLA-DR (Becton Dickinson), CD83 (Immunotech, Marseille, France) and CCR7 (BD Pharmingen, Milan, Italy) were used.

In Vivo monitoring
------------------

ATL or ATH (10 μg) and KLH (5 μg) were each suspended in 500 μl of PBS and injected intradermally into the forearm of the patient. PBS alone was used as negative control.

In Vitro immunomonitoring
-------------------------

### Evaluation of interferon-gamma-secreting cells

The patient\'s lymphocytes were collected and frozen before the first vaccination, after 4--6 vaccinations, and after 8--13 vaccinations. After thawing, 10 × 10^6^lymphocytes were stimulated *in vitro*overnight with ATL/ATH and 10 × 10^6^with KLH. Positive and negative controls were always included. Interferon-gamma (IFN-γ) secreting cells were detected using the IFN-γ Secretion Assay Cell Enrichment and Detection Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer\'s instructions.

Statistical evaluations
-----------------------

Survival time was calculated as the time between the date of the first cycle of therapy and the date of death from any cause. Survival curves were traced by the Kaplan-Meier method and the comparison between the two groups was based on the Log-Rank test. A two- sided P value of 5% was considered as significant. All analyses were performed using the R statistical software package.

Results
=======

Patient characteristics were as follows: 13 males, 8 females, with a median age of 52 years (range 35--75). Pretreatments, sites of evaluable disease, and PS are analytically described and analyzed in Table [1](#T1){ref-type="table"}, together with the HLA determination of each patient. Two patients older than 70 years but in good general conditions were enrolled onto the study and treated on a compassionate basis.

###### 

Patient characteristics

  **Patient ID**   **Sex**   **Age (Years)**   **PS (ECOG)**   **HLA**                                    **Site of Evaluable Disease**            **Pretreatments**
  ---------------- --------- ----------------- --------------- ------------------------------------------ ---------------------------------------- ------------------------
  1 L.A.           M         75                1               A~2~A~32~Cw~4~Cw~6~                        spleen, soft tissue                      IFN
  2 G.I.           F         66                0               A~24~A~11~B~44~B~18~Bw~4~Bw~6~Cw~5~Cw~7~   pelvis                                   CT+RT
  3 M.G.           M         73                1               A~1~A~10~B~13~B~41~Bw~4~Bw~6~              liver, lymph node                        CT
  4 S.P.           M         56                1               A~9~A~32~B~38~B~55~Bw~4~Bw~6~Cw~3~         lung, bone, lymph node                   BIOCT
  5 G.C.           M         51                0               A~1~A~2~B~8~B~35~Bw~6~Cw~4~Cw~7~           liver, lymph node                        IFN
  6 Z.V.           M         42                1               A~1~A~19~B~51~B~14~                        lung                                     BIOCT
  7 G.L.           M         56                2               A~3~A~28~B~35~B~53~Cw~4~                   liver                                    BIOCT
  8 B.A.           M         35                2               A~2~A~9~B~7~B~15~Bw~6~Cw~3~Cw~7~           lung, bone skin                          BIOCT
                                                                                                                                                   
                                                                                                                                                   
                                                                                                                                                   
  9 P.M.           M         45                0               A~1~A~9~B~17~Bw~4~Bw~6~Cw~3~Cw~4~          lung, lymph node                         BIO, BIOCT
  10 P.M.          M         52                0               A~11~A~31~B~14~B~60~Bw~6~Cw~3~             kidney, adrenal gland                    BIOCT
  11 R.L.          F         46                1               A~3~A~29~B~44~Bw~4~                        lung, liver, soft tissue                 CT
  12 G.D.          M         46                0               A~3~A~28~B~21~B~35~Cw~4~                   lymph node                               NT
  13 R.G.          M         65                1               A~10~B~8~B~38~Bw~4~Bw~6~Cw~7~              lung, soft tissue                        BIOCT
  14 T.A.          F         61                1               A~2~A~19~B~35~B~37~Bw~4~Bw~6~Cw~4~         soft tissue                              CT+RT
  15 B.A.          F         59                2               A~2~A~9~B~39~B~44~Bw~4~Bw~6~Cw~5~          liver, soft tissue                       BIOCT, locoregional CT
  16 C.P.          F         39                0               A~9~A~19~B~14~B~44~Bw~4~Bw~6~Cw~5~         kidney, soft tissue                      Locoregional CT
  17 O.M.          M         56                1               A~19~A~28~B~5~B~16~Bw4Bw~6~                lung, soft tissue                        BIOCT
  18 L.B.          F         39                2                                                          pelvis, lymph node                       BIOCT
  19 M.J.L.        F         37                0                                                          lung, kidney, lymph node, soft tissue    BIOCT
  20 O.G.          M         65                2               A~23~A~32~                                 adrenal gland, lymph node, soft tissue   BIOCT
  21 M.R.          F         38                0                                                          lymph node                               BIOCT
                                                                                                                                                   
                                                                                                          21 Viscera:                              13 BIOCT
                                                                                                           - 1 spleen                              3 BIO
                                                                                                           - 5 liver                               4 CT
                                                                                                           - 8 lung                                2 Locoregional CT
                                                                                                           - 3 kidney                              2 RT
                                                                                                           - 2 adrenal gland                       1 NT
                                                                                                           - 2 pelvis                              
                                                                                                          2 Bone                                   
                                                                                                          8 Lymph node                             
                                                                                                          9 Soft tissue                            

PS (ECOG) = performance status according ECOG; CT= chemotherapy; RT= radiotherapy;

BIO=Immunotherapy (Interferon, Inteleukin-2); BIOCT= chemotherapy+immunotherapy; NT= no treatment.

Male/Female 13/8

Median age 52 years (35--75).

P.S.: 0 = 8 ; 1 = 8; 2 = 5

The number of cells administered for each vaccination was about 10 × 10^6^, with a higher median for iDC (17 × 10^6^, range: 11--49.5) than for mDC (9.5 × 10^6^, range: 5.9--12.6). A total of 145 administrations (49 iDC and 96 mDC) were made.

DC phenotype characteristics are shown in Table [2](#T2){ref-type="table"}. iDC and mDC phenotyping was similar to that described in the literature, and there were no relevant differences in DC obtained from fresh or frozen tissue \[[@B4]\].

###### 

Surface expression of DC markers in infused DC\*

  ------------------------------------------------------
  **Marker**   **iDC**\              **mDC**\
               Median % (range)      Median % (range)
  ------------ --------------------- -------------------
  **CD1A**     **15.5**(0 -- 58)     **7**(0 -- 77)

  **CD14**     **0**(0 -- 17)        **4**(0 -- 67)

  **CD80**     **0**(0 -- 25)        **62**(2 -- 98)

  **CD83**     **0**(0 -- 25)        **47**(2 -- 86)

  **CD86**     **30**(0 -- 90)       **71**(5 -- 96)

  **HLA-DR**   **51.5**(3 -- 95)     **78**(13 -- 100)

  **CCR7**     **2.5**(0 -- 47)^§^   **45**(1 -- 91)
  ------------------------------------------------------

iDC, immature dendritic cells; mDC: mature dendritic cells.

^§^value calculated on 3/8 patients vaccinated with iDC.

\*Data represent the percentage of positive cells out of the total number of DC analyzed.

DC were pulsed with ATH in 9 cases, with ATH + ATL in 2 patients, and with ATL in 10 patients. During the course of the study we decided to continue using, where possible, only ATL-pulsed DC (ATL should, in theory, have a higher percentage of antigenic protein).

Clinical results
----------------

In the 8 patients treated with iDC, we observed 3 stabilizations (SD), each of 6 months\' duration, and 5 PD. Overall survival (OS) of the SD patients was 45, 26 and 7 months, whereas that of the PD patients ranged from 4 to 10 months. DTH positivity showed a weak response for both ATH and KLH in the patient with the longest survival (median OS 7.5 months, range 4--45). A weak positivity to only KLH was seen in the patient with a 26-month survival, whereas no response was observed in the remaining patients (Table [3A](#T3){ref-type="table"}).

###### 

Immunological and clinical response in patients vaccinated with iDC

  **Patient ID**        **No. of Vaccinations**    **Antigens (Type of Lysate)**   **Median No. of Administered Cells × 10**^6^**(range)**   **DTH Best Response after 4 or More Vaccinations**.   **Vitiligo**   **Clinical Response**   **Response Duration (Months)**   **Overall Survival (Months)**   
  --------------------- -------------------------- ------------------------------- --------------------------------------------------------- ----------------------------------------------------- -------------- ----------------------- -------------------------------- ------------------------------- ----
  1 L.A.                8                          H                               49.5 (15 -- 82)                                           \+                                                    \+                                     **SD**                           6                               45
  2 G.I.                5                          L                               13 (4.5 -- 26)                                            \-                                                    \+                                     **SD**                           6                               26
  3 M.G.                5                          L                               11 (7 -- 16.2)                                            \-                                                    \-             +/-                     **SD**                           6                               7
  4 S.P.                8                          L                               26.5 (10 -- 43.5)                                         \-                                                    \-                                     PD                               \-                              8
  5 G.C.                6                          L                               19 (9.6 -- 32)                                            \-                                                    \-                                     PD                               \-                              10
  6 Z.V.                5                          L/H                             11.3 (6.4 -- 21.5)                                        \-                                                    \-                                     PD                               \-                              4
  7 G.L.                6                          H                               22.6 (16.4 -- 48)                                         \-                                                    \-                                     PD                               \-                              5
  8 B.A.                4                          H                               15 (12 -- 51)                                             \-                                                    \-                                     PD                               \-                              5
                                                                                                                                                                                                                                                                                                           
  **No. of Patients**   **Administration Route**   **Site**                        **No. of Inoculations**                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                           
  8 iDC                 4 i.d. and 4 s.c.          6 inguinal and 2 axillary       6--8                                                                                                                                                                                                                    

DTH, delayed-type hypersensitivity; L, autologus lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin; SD, stabilization; PD, progressive disease.

i.d., intradermal; s.c., subcutaneous

In the 13 mDC-treated patients, one complete response (CR) of 8 months\' duration (OS = 32+ months), one partial response (PR) lasting 3 months (OS = 14 months) and 2 mixed responses (MR) of 12 and 6 months\' duration (OS = 28+ and 22 months, respectively) were obtained. There were also 3 SD lasting 7+, 6 and 3+ months (the third patient is still undergoing treatment) (OS = 7+, 14 and 3+ months, respectively) and 6 PD with a median OS of 5.5 months (range 3--20). Median OS was 8 months (range 3--32+).

Patient no. 12 (46-year old man), who had numerous metastatic abdominal and pelvic lymph node localizations, obtained a CR of 8 months, and was the only patient who had not received previous treatment. He developed vitiligo (Figure [1](#F1){ref-type="fig"}) and the DTH test confirmed a good response to ATL and KLH. Baseline and first-evaluation CT scan images are shown in Figure [2](#F2){ref-type="fig"}. Patient no. 9 rapidly obtained a PR for lung and lymph node lesions but developed brain metastases after only 3 months. MR was observed in patient nos. 10 and 14, in whom subcutaneous and lymph node metastases disappeared and reappeared for 6 and 12 months, respectively. These patients showed positive DTH for KLH, the former also a strong positive reaction for ATL. All data are analytically reported in Table [3B](#T4){ref-type="table"}.

###### 

Immunological and clinical response in patients vaccinated with mDC

  **Patient ID**        **No. of Vaccinations**    **Antigens (Type of Lysate)**   **Median No. of Administered Cells × 10**^6^**(range)**   **DTH Best Response after 4 or More Vaccinations**   **Vitiligo**   **Clinical Response**   **Response Duration (Months)**   **Overall Survival (Months)**   
  --------------------- -------------------------- ------------------------------- --------------------------------------------------------- ---------------------------------------------------- -------------- ----------------------- -------------------------------- ------------------------------- -----
  9 P.M.                7                          L                               11.4 (9 -- 24.1)                                          \-                                                   \-                                     **PR**                           3                               14
  10 P.M.               15                         L                               15 (2.8 -- 24)                                            ++                                                   ++++                                   **MR**                           6                               22
  11 R.L.               10                         H                               9.5 (4 -- 13.4)                                           \-                                                   ++                                     **SD**                           9                               14
  12 G.D.               16                         L/H                             12.6 (2.8 -- 20.8)                                        ++                                                   +++            \+                      **CR**                           8                               32+
  13 R.G.               4                          H                               9.3 (8 -- 26)                                             \-                                                   +++                                    PD                               \-                              8
  14 T.A.               13                         H                               9 (1.2 -- 12)                                             \-                                                   ++                                     **MR**                           12                              28+
  15 B.A.               4                          H                               5.9 (3.7 -- 12)                                           \-                                                   \-                                     PD                               \-                              7
  16 C.P.               6                          H                               7.8 (1.6 -- 15)                                           \-                                                   ++                                     PD                               \-                              20
  17 O.M.               4                          H                               11.5 (10 -- 21)                                           \-                                                   \-                                     PD                               \-                              5
  18 L.B.               4                          L                               12.5 (10 -- 15.5)                                         \-                                                   \-                                     PD                               \-                              3
  19 M.J.L.             8                          L                               6 (2.2 -- 10)                                             \+                                                   +++            \+                      **SD**                           7+                              7+
  20 O.G.               5                          L                               10 (8.8 -- 12.3)                                          \-                                                   \-                                     PD                               \-                              3
  21 M.R.               4                          L                               9.2 (8 -- 10)                                             \+                                                   ++                                     **SD (u.t.)**                    3+                              3+
                                                                                                                                                                                                                                                                                                          
  **No. of Patients**   **Administration Route**   **Site**                        **No. of Inoculations**                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                          
  13 mDC                13 i.d.                    10 inguinal and 3 axillary      8--10                                                                                                                                                                                                                  

DTH, delayed-type hypersensitivity; L, autologous lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin.

PD, progressive disease; MR, mixed response; SD, stabilization; PR, partial response; CR, complete response; u.t., undergoing treatment.

i.d., intradermal; s.c., subcutaneous

![Onset of vitiligo in patient no.12 who had CR after treatment with mDC.](1479-5876-4-36-1){#F1}

![Baseline and post 4^th^vaccination CT scan of patient no. 12, treated with mDC. The patient had an 8-month CR of the abdominal soft tissue lesions.](1479-5876-4-36-2){#F2}

The OR percentage for the 21 patients treated was 19%, which increased to 30.7% (4/13) when only the results obtained with mDC were considered. The overall percentage of patients who did not progress was 47.6% (10/21), rising to 53.8 % (7/13) for those treated with mDC. Our data do not seem to have been influenced by age, sex, or HLA distribution (in 8/10 patients there was a distribution of 2 patients for each of the principle alleles, A1, A2, A3 and A11). There does not appear to be any specific correlation between response and site of disease or type of pretreatment, although it should be remembered that the only patient who obtained a CR had not been pretreated. Futhermore, the number of cells injected would not appear to affect response.

Conversely, initial PS may have exerted an influence on response; all 5 patients with PS = 2 at baseline progressed. Clinical response obviously correlated positively with OS: 11 patients with progressive disease (PD) had a median OS of 5 months (range 3--20), whereas the 10 who did not progress had a median OS of 21 months (range 3^+^-- 45).

Toxicity
--------

Apart from swelling, redness and pruritus around the site of inoculation, no noteworthy toxicities or side-effects were observed. A low fever with mild flu-like symptoms (grade 1--2) accompanied the administration of IL-2 from the 3rd to the 7th day of treatment. No autoimmune phenomena were observed apart from the onset of vitiligo in 2 patients and the flaring up of a pre-existing vitiligo in a third patient.

In Vivo immunomonitoring
------------------------

Amongst the 10 patients with non progressive disease (NPD), only 2 had completely negative DTH reactions for both KLH and ATL/ATH, whereas the 5 patients who developed a response to ATL/ATH were all responders. Correlating this with OS, it can be seen that, amongst patients with a positive DTH reaction (10 patients, 8 of whom had NPD), median survival was 24 months (range 3^+^-45), whereas those with negative DTH (11 patients, 2 of whom had NPD), had a median OS of 5 months (range 3--14). The actuarial curve of survival in relation to a positive or negative DTH reaction shows that 24-month OS was 51% in DTH+ patients compared to 0% in DTH- patients (P \< 0.001) at a median follow-up of 32 months (Figure [3](#F3){ref-type="fig"}). None of the patients who began treatment with a PS of 2 showed a positive DTH test.

![Actuarial curves of overall survival (OS) based on DTH results. Eleven patients had negative DTH with a median OS of 5 months and no survival at 24 months. Ten patients had positive DTH (for ATL/ATH and/or for KLH) and a median OS of 24 months, with 50% still alive after 2 years (P \< 0.001).](1479-5876-4-36-3){#F3}

In Vitro immunomonitoring
-------------------------

*In vitro*immunomonitoring was performed by evaluating the number of lymphocytes in peripheral blood that are capable of producing gamma-IFN after stimulation with KLH and ATL/ATH. The test was only commercialized recently and was carried out on 10 patients (1 treated with iDC and 9 with mDC).

Clinical responses in 7 patients corresponded with the indications of the test (70%): positivity was correlated with NPD in 4 cases and with PD in 3 patients. Comparing the results from the *in vitro*test with those of DTH stimulation using both KLH and ATL/ATH, overall concordance was 75% (Table [4](#T5){ref-type="table"}).

###### 

*In vitro*immunomonitoring (Miltenyi Test): comparison between IFN-γ secreting lymphocytes after stimulation with KLH and ATL/ATH, and DTH test and clinical outcome

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient ID**   **Stimulation**   **Baseline**   **After 4/6 Vaccinations**   **After 8/13 Vaccinations**   **DTH**        **Clinical Response**   
  ---------------- ----------------- -------------- ---------------------------- ----------------------------- -------------- ----------------------- --------
  4 S.P.^a^        KLH               0              0                                                          **Negative**   **PD**                  

                   L                 0              0                                                          **Negative**                           

  9 P.M.^b^        KLH                              0                                                          **Negative**   PR                      

                   L                                0                                                          **Negative**                           

  10\                                KLH            0                            0                             186            **Positive**            **MR**
  P.M.^b^                                                                                                                                             

                   L                 0              0                            0                             Positive                               

  12\                                KLH            133                          1238                          2253           **Positive**            **CR**
  G.D.^b^                                                                                                                                             

                   L                 56             456                          13405                         **Positive**                           

  14 T.A.^b^       KLH               4              356                          73                            **Positive**   **MR**                  

                   H                 0              0                            0                             Negative                               

  16 C.P.^b^       KLH               0              103                                                        Positive       PD                      

                   H                 0              0                                                          **Negative**                           

  18 L.B.^b^       KLH               264            110                                                        **Negative**   **PD**                  

                   L                 0              0                                                          **Negative**                           

  19\                                KLH            0                            0                                            Positive                SD
  M.J.L.^b^                                                                                                                                           

                   L                 0              0                                                          Positive                               

  20\                                KLH            0                            0                                            **Negative**            **PD**
  O.M.^b^                                                                                                                                             

                   L                 0              0                                                          **Negative**                           

  21\                                KLH            0                            99                                           **Positive**            **SD**
  M.R.^b^                                                                                                                                             

                   L                 0              292                                                        **Positive**                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

DTH, delayed-type hypersensitivity; L, autologous tumor lysate; H, autologous tumor homogenate; KLH, keyhole limpet hemocyanin.

^a^= pts treated with iDC.

^b^= pts treated with mDC.

**bold**= data corresponding to test

Discussion
==========

The practice of antitumor vaccination with DC has brought with it new hope, especially for patients with melanoma, who obtain unsatisfactory results from traditional therapies \[[@B30],[@B31]\]. The high number of known tumor antigens makes melanoma a good target for vaccine therapy \[[@B8]\]. DC vaccination is generally easy to administer and induces low toxicity, but studies published to date are difficult to compare with each other because of the small cases series involved, the limited number of clinical responses observed, and the numerous methodologies of DC preparation used: Cranmer, in fact, recently listed up to 12 possible variations in culture methodology and treatment modalities \[[@B32]\].

Crucial issues such as the best antigens or the most effective evaluation criteria to use have still to be clarified. DC derived from peripheral blood rather than from bone marrow tend to be used and it has been seen that mDC are undoubtedly better at migrating to regional lymph nodes and are more effective at determining an immunological and clinical response than iDC \[[@B14],[@B33],[@B34]\]. It has also recently been reported that intradermal administration results in a higher DC migration than subcutaneous injection \[[@B21],[@B35]\].

However, one of the main problems of vaccination therapy remains the type of antigens to use. Pulsing DC with known single peptides enables us to accurately monitor immunization, but literature results highlight poor, short-term clinical responses, probably due to tumor escape \[[@B36],[@B37]\]. Whilst pulsing with tumor extracts (lysate, apoptotic bodies, heat shock proteins, etc.) theoretically implies that all tumor antigens are represented, it also complicates the process of specific immunomonitoring, requires sizeable quantities of tumor tissue, and results in DC being loaded with a large number of other non antigenic proteins that could reduce, in terms of percentages, the efficacy of the exposure \[[@B6],[@B38]-[@B41]\]. Novel methods of pulsing with tumor RNA or with a selection of RNA antigens could perhaps result in increased immune efficacy, especially if we bear in mind the large number of melanoma-restricted genes that have already been identified and codified \[[@B9],[@B42]\].

Clinical evaluation also poses a problem. There is a growing need to modify RECIST criteria, widely used in oncology, when assessing clinical responses in vaccine therapy, *e.g.*to define *mixed*responses or responses that occur after an initial progression. Once a vaccine strategy has been clarified or better defined, a modified integrated system of clinical evaluation will be needed \[[@B43]\].

New strategies must also be sought to overcome tumor immunosuppression \[[@B44],[@B45]\]. The use of lymphoablative chemotherapy has been hypothesized to reduce or eliminate the component of T-regulator lymphocytes before vaccination \[[@B46]-[@B49]\]. Studies in this area could also clarify the still controversial role of IL-2 as a vaccine adjuvant \[[@B50]-[@B53]\] and could help to provide valuable information about new molecular targets or cytokines \[[@B54],[@B55]\].

Recent publications would seem to indicate that the presence and/or activation of specific lymphocytes induced by immunostimulation correlates positively with survival \[[@B56]-[@B59]\]. Our results concur with this finding and also indicate the need for a better selection of patients, especially in view of the fact that poor PS would seem to correlate with no clinical or immunological response. Patients with minimal residual disease or evidence of probable immunocompetence can be considered candidates for controlled vaccine trials \[[@B60],[@B61]\].

In conclusion, although vaccination treatment with DC pulsed with KLH and ATL/ATH is an experimental approach and still requires numerous adjustments and verifications, it would seem to be practicable, non toxic, and most importantly, effective in prolonging OS if administered in a subgroup of patients who show immunoreactivity.
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